Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrea L M Silber

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Connecticut Medicine|August 4, 2012
Comprehensive cancer control--impacting every physicianAndrew L Salner, Andrea L M Silber
Connecticut Medicine|August 4, 2012
A medical home for a breast cancer survivorRobert J Nardino, Andrea L M Silber
Oncology (Williston Park, N.Y.)|February 17, 2017
New Therapeutic Strategies for Triple-Negative Breast CancerBorbála Székely, Andrea L M Silber, Lajos Pusztai
JCO Clinical Cancer Informatics|January 19, 2019
Bidirectional Text Messaging to Monitor Endocrine Therapy Adherence and Patient-Reported Outcomes in Breast CancerSarah S Mougalian, Lianne N Epstein, Ami P Jhaveri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2024
Phase III Randomized, Placebo-Controlled Trial of Endocrine Therapy ± 1 Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive, Early-Stage Breast CancerMariana Chavez-MacGregor, Jieling Miao, Lajos Pusztai, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Connecticut Medicine|August 4, 2012
Comprehensive cancer control--impacting every physicianAndrew L Salner, Andrea L M Silber
Connecticut Medicine|August 4, 2012
A medical home for a breast cancer survivorRobert J Nardino, Andrea L M Silber
Oncology (Williston Park, N.Y.)|February 17, 2017
New Therapeutic Strategies for Triple-Negative Breast CancerBorbála Székely, Andrea L M Silber, Lajos Pusztai
JCO Clinical Cancer Informatics|January 19, 2019
Bidirectional Text Messaging to Monitor Endocrine Therapy Adherence and Patient-Reported Outcomes in Breast CancerSarah S Mougalian, Lianne N Epstein, Ami P Jhaveri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2024
Phase III Randomized, Placebo-Controlled Trial of Endocrine Therapy ± 1 Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive, Early-Stage Breast CancerMariana Chavez-MacGregor, Jieling Miao, Lajos Pusztai, et al.
Pageof 1